eMedicine Specialties > Oncology > none

Thyroid Lymphoma

Author: Fernando Cabanillas, MD, Chairman, Professor, Department of Hematology, Division of Lymphoma/Myeloma, MD Anderson Cancer Center, University of Texas
Contributor Information and Disclosures

Updated: May 17, 2007

Introduction

Background

Primary thyroid lymphoma can be defined as a lymphoma that arises from the thyroid gland. This definition excludes lymphomas that invade the thyroid gland because of either metastasis or direct extension from an adjacent lymph node. Primary thyroid lymphomas usually are of the non-Hodgkin type. Primary thyroid Hodgkin disease is extremely rare. Non-Hodgkin lymphomas (NHLs) can be further divided into aggressive and indolent cell types.

The aggressive NHLs comprise a large number of cell types, the most common of which is large-cell lymphoma. NHLs most frequently arise from lymph nodes, but an extranodal site is the primary source in approximately 30% of cases, and the thyroid gland is among the most common of these extranodal sites.

Pathophysiology

Of interest, these disorders are frequently associated with Hashimoto thyroiditis, and the incidence of primary thyroid lymphomas in patients with Hashimoto thyroiditis is markedly increased; some believe that a pathogenetic link exists between this autoimmune disorder and thyroid NHL.1 The proposed theory hypothesizes that chronic antigenic stimulation secondary to the autoimmune disorder leads to chronic proliferation of lymphoid tissue, which eventually undergoes a mutation that results in clonal proliferation, leading to the development of lymphoma. Hypothyroidism has been observed in 30-40% of patients with thyroid lymphoma.

Frequency

United States

Thyroid lymphomas constitute only 3% of all NHLs and approximately 5% of all thyroid neoplasms2,3,4 . Although thyroid NHL is not common, it is highly curable without extensive surgery; for this reason, it should be recognized early and treated correctly.

Mortality/Morbidity

Primary thyroid lymphoma, as discussed in this article, is a highly curable malignancy if diagnosed promptly and managed correctly.

Sex

As expected, because of its association with Hashimoto thyroiditis, thyroid lymphomas are more common in women than in men, with a ratio ranging from 2:1 to as high as 14:1 in some series3,5 .

Age

Similar to other NHLs, thyroid lymphomas usually affect patients with a median age of 60 years6 .

Clinical

History

The most common clinical presentation is that of a rapidly enlarging thyroid mass, frequently in association with neck adenopathy6 (see Image 1). With the exception of anaplastic thyroid carcinoma, thyroid NHL usually grows faster than any other thyroid neoplasm; however, low-grade or indolent NHLs occasionally can arise in the thyroid gland, and their growth rate is slower. Hoarseness, respiratory difficulty, cough, and dysphagia also can occur as presenting symptoms.

Physical

Patients with large-cell thyroid lymphoma usually present with a rapidly growing thyroid nodule; however, those with an indolent histology (eg, those with a mucosa-associated lymphoid tissue [MALT] lymphoma) present with a slow-growing node, which can grow for months or years before it is brought to the physician's attention. Neck adenopathy can also be present in association with the thyroid nodule.

More on Thyroid Lymphoma

Overview: Thyroid Lymphoma
Differential Diagnoses & Workup: Thyroid Lymphoma
Treatment & Medication: Thyroid Lymphoma
Follow-up: Thyroid Lymphoma
Multimedia: Thyroid Lymphoma
References
[ CLOSE WINDOW ]

References

  1. Holm LE, Blomgren H, Lowhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med. Mar 7 1985;312(10):601-4. [Medline].

  2. Ansell SM, Grant CS, Habermann TM. Primary thyroid lymphoma. Semin Oncol. Jun 1999;26(3):316-23. [Medline].

  3. Austin JR, el-Naggar AK, Goepfert H. Thyroid cancers. II. Medullary, anaplastic, lymphoma, sarcoma, squamous cell. Otolaryngol Clin North Am. Aug 1996;29(4):611-27. [Medline].

  4. Pasieka JL. Anaplastic cancer, lymphoma, and metastases of the thyroid gland. Surg Oncol Clin N Am. Oct 1998;7(4):707-20. [Medline].

  5. Tupchong L, Hughes F, Harmer CL. Primary lymphoma of the thyroid: clinical features, prognostic factors, and results of treatment. Int J Radiat Oncol Biol Phys. Oct 1986;12(10):1813-21. [Medline].

  6. Ha CS, Shadle KM, Medeiros LJ, et al. Localized non-Hodgkin lymphoma involving the thyroid gland. Cancer. Feb 15 2001;91(4):629-35. [Medline].

  7. Velasquez WS, Jagannath S, Tucker SL, et al. Risk classification as the basis for clinical staging of diffuse large- cell lymphoma derived from 10-year survival data. Blood. Aug 1 1989;74(2):551-7. [Medline].

  8. Swan F Jr, Velasquez WS, Tucker S, et al. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol. Oct 1989;7(10):1518-27. [Medline].

  9. Pappa VI, Hussain HK, Reznek RH, et al. Role of image-guided core-needle biopsy in the management of patients with lymphoma. J Clin Oncol. Sep 1996;14(9):2427-30. [Medline].

  10. Isaacson PG. Lymphoma of the thyroid gland. Curr Top Pathol. 1997;91:1-14. [Medline].

  11. International Non-Hodgkin Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. Sep 30 1993;329(14):987-94. [Medline].

  12. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. Jul 2 1998;339(1):21-6. [Medline].

  13. Matsuzuka F, Miyauchi A, Katayama S, et al. Clinical aspects of primary thyroid lymphoma: diagnosis and treatment based on our experience of 119 cases. Thyroid. Summer 1993;3(2):93-9. [Medline].

  14. Rodriguez J, Cabanillas F, McLaughlin P, et al. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'. Ann Oncol. Nov 1992;3(9):711-7. [Medline].

  15. Glick JH, Kim K, Earle J, et al. An ECOG randomized phase III trial of CHOP vs. CHOP + radiotherapy (XRT) for intermediate grade early stage non-Hodgkin's lymphoma (NHL) [abstract]. Proceedings of the American Society of Clinical Oncology. 1995;14 (A-1221):391.

  16. Laing RW, Hoskin P, Hudson BV, et al. The significance of MALT histology in thyroid lymphoma: a review of patients from the BNLI and Royal Marsden Hospital. Clin Oncol (R Coll Radiol). 1994;6(5):300-4. [Medline].

  17. Miller TP, Dahlberg S, Cassidy JR, et al. Three cycles of CHOP (CHOP-3) plus radiotherapy (RT) is superior to eight cycles of CHOP (CHOP-8) alone for localized intermediate grade non-Hodgkin's lymphoma (NHL). A Southwest Oncology Group study. Proc Ann Meet Am Soc Clin Oncol. 1996;15 (A1257):411.

  18. Ito Y, Yoshida H, Matsuzuka F, et al. Cdc25A and cdc25B expression in malignant lymphoma of the thyroid: Correlation with histological subtypes and cell proliferation. Int J Mol Med. Mar 2004;13(3):431-5. [Medline].

  19. Macchiarini P, Ostertag H. Uncommon primary mediastinal tumours. Lancet Oncol. Feb 2004;5(2):107-18. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

thyroid MALT, thyroid large cell lymphoma, thyroid large-cell lymphoma, primary thyroid lymphomas, non-Hodgkin lymphomas, non-Hodgkin's lymphomas, NHLs, Hashimoto thyroiditis, Hashimoto's thyroiditis, thyroid cancer

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Fernando Cabanillas, MD, Chairman, Professor, Department of Hematology, Division of Lymphoma/Myeloma, MD Anderson Cancer Center, University of Texas
Fernando Cabanillas, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for Cancer Research, American Association for the Advancement of Science, American College of Physicians-American Society of Internal Medicine, American Society of Clinical Oncology, American Society of Hematology, New York Academy of Sciences, and Texas Medical Association
Disclosure: Nothing to disclose.

Medical Editor

Lodovico Balducci, MD, Professor of Oncology and Medicine, University of South Florida College of Medicine; Division Chief, Senior Adult Oncology Program, H Lee Moffitt Cancer Center and Research Institute
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Wendy Hu, MD, Consulting Staff, Department of Hematology/Oncology and Bone Marrow Transplantation, Huntington Memorial Medical Center
Wendy Hu, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Society for Blood and Marrow Transplantation, American Society of Clinical Oncology, American Society of Hematology, and Physicians for Social Responsibility
Disclosure: Nothing to disclose.

CME Editor

Rajalaxmi McKenna, MD, FACP, Consulting Staff, Department of Medicine, Southwest Medical Consultants, SC, Good Samaritan Hospital, Advocate Health Systems
Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, and International Society on Thrombosis and Haemostasis
Disclosure: Nothing to disclose.

Chief Editor

John S Macdonald, MD, Professor of Medicine, New York Medical College; Chief, St Vincent's Hospital and Medical Center; Medical Director, Division of Medical Oncology, Saint Vincent's Comprehensive Cancer Center
John S Macdonald, MD is a member of the following medical societies: American Association for Cancer Research, American Cancer Society, American College of Clinical Pharmacology, American College of Physicians, American Federation for Medical Research, American Society of Clinical Oncology, Pennsylvania Medical Society, Philadelphia County Medical Society, Sigma Xi, Southern Association for Oncology, and Southern Medical Association
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.